CY1119850T1 - Χρηση της μετφορμινης σε συνδυασμο με ενεργοποιητη γλυκοκινασης και συνθεσεων που περιλαμβανουν μετφορμινη και ενεργοποιητη γλυκοκινασης - Google Patents
Χρηση της μετφορμινης σε συνδυασμο με ενεργοποιητη γλυκοκινασης και συνθεσεων που περιλαμβανουν μετφορμινη και ενεργοποιητη γλυκοκινασηςInfo
- Publication number
- CY1119850T1 CY1119850T1 CY20181100011T CY181100011T CY1119850T1 CY 1119850 T1 CY1119850 T1 CY 1119850T1 CY 20181100011 T CY20181100011 T CY 20181100011T CY 181100011 T CY181100011 T CY 181100011T CY 1119850 T1 CY1119850 T1 CY 1119850T1
- Authority
- CY
- Cyprus
- Prior art keywords
- metformin
- activator
- combination
- glykinase
- interactive
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/54—Nitrogen and either oxygen or sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Η παρούσα εφεύρεση προσφέρει τις χρήσεις ενεργοποιητή γλυκοκινάσης σε συνδυασμό με μετφορμίνη. Οι χρήσεις περιλαμβάνουν θεραπεία του διαβήτη τύπου 2, μείωση της γλυκόζης αίματος, βελτίωση της ευαισθησίας στην ινσουλίνη, ενίσχυση της φωσφορυλίωσης της γλυκόζης και βελτίωση της θεραπευτικής αποτελεσματικότητας της μετφορμίνης. Η εφεύρεση προσφέρει επίσης φαρμακευτικές συνθέσεις που περιλαμβάνουν ενεργοποιητή ΓΚ και μετφορμίνη. Η εφεύρεση προσφέρει επίσης άλας που έχει σχηματιστεί μεταξύ μετφορμίνης και ενεργοποιητή ΓΚ.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34855410P | 2010-05-26 | 2010-05-26 | |
| PCT/US2011/037752 WO2011149945A1 (en) | 2010-05-26 | 2011-05-24 | Use of metformin in combination with a glucokinase activator and compositions comprising metformin and a glucokinase activator |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1119850T1 true CY1119850T1 (el) | 2018-06-27 |
Family
ID=45004334
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100011T CY1119850T1 (el) | 2010-05-26 | 2018-01-04 | Χρηση της μετφορμινης σε συνδυασμο με ενεργοποιητη γλυκοκινασης και συνθεσεων που περιλαμβανουν μετφορμινη και ενεργοποιητη γλυκοκινασης |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US9359313B2 (el) |
| EP (1) | EP2576524B1 (el) |
| JP (1) | JP5902676B2 (el) |
| KR (2) | KR101878252B1 (el) |
| CN (1) | CN102906077B (el) |
| AU (1) | AU2011258460B2 (el) |
| BR (1) | BR112012029844A2 (el) |
| CA (1) | CA2799591C (el) |
| CO (1) | CO6640324A2 (el) |
| CY (1) | CY1119850T1 (el) |
| DK (1) | DK2576524T3 (el) |
| EA (1) | EA032085B1 (el) |
| ES (1) | ES2655396T3 (el) |
| HR (1) | HRP20180113T1 (el) |
| HU (1) | HUE036009T2 (el) |
| IL (1) | IL223137A0 (el) |
| LT (1) | LT2576524T (el) |
| ME (1) | ME03007B (el) |
| MX (1) | MX347372B (el) |
| NO (1) | NO2576524T3 (el) |
| NZ (1) | NZ603614A (el) |
| PE (1) | PE20130275A1 (el) |
| PL (1) | PL2576524T3 (el) |
| PT (1) | PT2576524T (el) |
| RS (1) | RS56761B1 (el) |
| SG (1) | SG185660A1 (el) |
| SI (1) | SI2576524T1 (el) |
| SM (1) | SMT201800140T1 (el) |
| TW (1) | TWI508723B (el) |
| WO (1) | WO2011149945A1 (el) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012029844A2 (pt) | 2010-05-26 | 2015-10-13 | Transtech Pharma Inc | uso de metamorfina em combinação com um ativador de glucoquinase e combinações compreendendo metamorfina com um ativador de glucoquinase |
| EP2849776B1 (en) * | 2012-05-17 | 2021-04-21 | vTv Therapeutics LLC | Glucokinase activator compositions for the treatment of diabetes |
| KR20150126362A (ko) * | 2013-03-04 | 2015-11-11 | 브이티브이엑스 홀딩스 아이 엘엘씨 | 글루코키나제 활성화제를 포함하는 고체 조성물 및 그것의 제조 및 사용 방법 |
| EP2964198A2 (en) * | 2013-03-04 | 2016-01-13 | vTv Therapeutics LLC | Stable glucokinase activator compositions |
| US10988442B2 (en) * | 2016-11-09 | 2021-04-27 | Novomedix, Llc | Nitrite salts of 1,1-dimethylbiguanide, pharmaceutical compositions, and methods of use |
| CA3101832A1 (en) * | 2018-05-31 | 2019-12-05 | Hua Medicine (Shanghai) Ltd. | Pharmaceutical combination, composition and formulation containing glucokinase activator and a-glucosidase inhibitor, preparation methods and uses thereof |
| EP4487909A3 (en) * | 2018-06-12 | 2025-03-19 | vTv Therapeutics LLC | Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs |
| US12391658B2 (en) | 2020-02-18 | 2025-08-19 | Vtv Therapeutics Llc | Sulfoxide and sulfone glucokinase activators and methods of use thereof |
| CA3181722A1 (en) * | 2020-06-08 | 2021-12-16 | Jing TENG | Salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid and uses thereof |
| EP4161639A4 (en) * | 2020-06-08 | 2024-01-17 | vTv Therapeutics LLC | CRYSTALLINE FORMS OF ACETIC ACID {2-[3-CYCLOHEXYL-3-(TRANS-4-PROPOXY-CYCLOHEXYL)-UREIDO]-THIAZOL-5-YLSULFANYL} AND THEIR USES |
| CN115073330A (zh) * | 2021-03-15 | 2022-09-20 | 中国医学科学院药物研究所 | 二甲双胍肉桂酸盐及制备方法和其组合物与用途 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT323195B (de) * | 1973-03-16 | 1975-06-25 | Hurka Wilhelm | Verfahren zur herstellung neuer salze von biguaniden |
| FR2243684B1 (el) | 1973-09-19 | 1977-01-28 | Semb | |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4356108A (en) | 1979-12-20 | 1982-10-26 | The Mead Corporation | Encapsulation process |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| WO2004002481A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
| ITRM20030053A1 (it) * | 2003-02-10 | 2004-08-11 | Sigma Tau Ind Farmaceuti | Associazione di farmaci antidiabetici. |
| AU2003269484A1 (en) * | 2003-09-11 | 2005-03-29 | Biocon Limited | Salt of atorvastatin with metformin |
| MXPA06007667A (es) | 2004-01-06 | 2006-09-01 | Novo Nordisk As | Heteroaril-ureas y su uso como activadores de glucocinasa. |
| JP2008515818A (ja) * | 2004-10-07 | 2008-05-15 | ステム セル セラピューティクス コーポレイション | 妊娠に関連する化合物の投与による多能性幹細胞の増殖の刺激 |
| EP1904438B1 (en) * | 2005-07-08 | 2012-02-29 | Novo Nordisk A/S | Dicycloalkylcarbamoyl ureas as glucokinase activators |
| JP2009500377A (ja) * | 2005-07-08 | 2009-01-08 | ノボ・ノルデイスク・エー／エス | ジシクロアルキルウレア型グルコキナーゼ活性化剤 |
| JP4960355B2 (ja) * | 2005-07-14 | 2012-06-27 | ノボ・ノルデイスク・エー／エス | ウレア型グルコキナーゼ活性化剤 |
| WO2008084043A1 (en) | 2007-01-09 | 2008-07-17 | Novo Nordisk A/S | Urea glucokinase activators |
| MY152749A (en) | 2008-05-16 | 2014-11-28 | Takeda California Inc | Pyrazole and fused pyrazole glucokinase activators |
| WO2011025270A2 (ko) * | 2009-08-25 | 2011-03-03 | 한올바이오파마주식회사 | 메트포르민 카페익산염, 그의 제조방법, 그를 포함하는 약학조성물 및 그를 포함하는 복합제제 |
| BR112012029844A2 (pt) * | 2010-05-26 | 2015-10-13 | Transtech Pharma Inc | uso de metamorfina em combinação com um ativador de glucoquinase e combinações compreendendo metamorfina com um ativador de glucoquinase |
| EP2849776B1 (en) | 2012-05-17 | 2021-04-21 | vTv Therapeutics LLC | Glucokinase activator compositions for the treatment of diabetes |
| KR20150126362A (ko) | 2013-03-04 | 2015-11-11 | 브이티브이엑스 홀딩스 아이 엘엘씨 | 글루코키나제 활성화제를 포함하는 고체 조성물 및 그것의 제조 및 사용 방법 |
| EP2964198A2 (en) | 2013-03-04 | 2016-01-13 | vTv Therapeutics LLC | Stable glucokinase activator compositions |
-
2011
- 2011-05-24 BR BR112012029844A patent/BR112012029844A2/pt not_active IP Right Cessation
- 2011-05-24 LT LTEP11787250.7T patent/LT2576524T/lt unknown
- 2011-05-24 ME MEP-2018-24A patent/ME03007B/me unknown
- 2011-05-24 JP JP2013512164A patent/JP5902676B2/ja active Active
- 2011-05-24 EA EA201201617A patent/EA032085B1/ru not_active IP Right Cessation
- 2011-05-24 EP EP11787250.7A patent/EP2576524B1/en active Active
- 2011-05-24 PL PL11787250T patent/PL2576524T3/pl unknown
- 2011-05-24 NO NO11787250A patent/NO2576524T3/no unknown
- 2011-05-24 KR KR1020187006115A patent/KR101878252B1/ko active Active
- 2011-05-24 PT PT117872507T patent/PT2576524T/pt unknown
- 2011-05-24 RS RS20180055A patent/RS56761B1/sr unknown
- 2011-05-24 PE PE2012002211A patent/PE20130275A1/es not_active Application Discontinuation
- 2011-05-24 CA CA2799591A patent/CA2799591C/en active Active
- 2011-05-24 SM SM20180140T patent/SMT201800140T1/it unknown
- 2011-05-24 US US13/114,964 patent/US9359313B2/en active Active
- 2011-05-24 SG SG2012085080A patent/SG185660A1/en unknown
- 2011-05-24 AU AU2011258460A patent/AU2011258460B2/en active Active
- 2011-05-24 MX MX2012013617A patent/MX347372B/es active IP Right Grant
- 2011-05-24 NZ NZ603614A patent/NZ603614A/en not_active IP Right Cessation
- 2011-05-24 HU HUE11787250A patent/HUE036009T2/hu unknown
- 2011-05-24 DK DK11787250.7T patent/DK2576524T3/en active
- 2011-05-24 HR HRP20180113TT patent/HRP20180113T1/hr unknown
- 2011-05-24 ES ES11787250.7T patent/ES2655396T3/es active Active
- 2011-05-24 WO PCT/US2011/037752 patent/WO2011149945A1/en not_active Ceased
- 2011-05-24 KR KR1020127033687A patent/KR101860120B1/ko active Active
- 2011-05-24 SI SI201131369T patent/SI2576524T1/en unknown
- 2011-05-24 CN CN201180025744.3A patent/CN102906077B/zh active Active
- 2011-05-25 TW TW100118368A patent/TWI508723B/zh active
-
2012
- 2012-11-19 IL IL223137A patent/IL223137A0/en not_active IP Right Cessation
- 2012-12-21 CO CO12232453A patent/CO6640324A2/es not_active Application Discontinuation
-
2016
- 2016-02-11 US US14/988,143 patent/US9855251B2/en active Active
-
2017
- 2017-08-28 US US15/687,824 patent/US10064846B2/en active Active
-
2018
- 2018-01-04 CY CY20181100011T patent/CY1119850T1/el unknown
- 2018-08-08 US US16/058,512 patent/US10363244B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1119850T1 (el) | Χρηση της μετφορμινης σε συνδυασμο με ενεργοποιητη γλυκοκινασης και συνθεσεων που περιλαμβανουν μετφορμινη και ενεργοποιητη γλυκοκινασης | |
| CY1124298T1 (el) | Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet | |
| CY1122428T1 (el) | Θεραπευτικη αγωγη της παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας με διειδικα αντισωματα εναντι cd3xcd19 | |
| CY1120030T1 (el) | Διπλοι glp1/gip ή τριγωνικοι αγωνιστες glp1/gip/ γλυκαγονης | |
| CY1111354T1 (el) | Συστασεις αναστολεα ddp iv | |
| CY1115350T1 (el) | Χρησεις αναστολεων της dpp iv | |
| CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
| CY1117603T1 (el) | Η λιξισενατιδη ως προσθετο στη μετφορμινη στην θεραπευτικη αγωγη του διαβητη τυπου 2 | |
| CY1124135T1 (el) | Δοσολογικα σχηματα για την αγωγη της νοσου ρομρε | |
| CY1121853T1 (el) | Συνδυαστικη θεραπεια για την αγωγη του διαβητη | |
| CY1120389T1 (el) | Φαρμακευτικη συνθεση που περιλαμβανει εναν glp-1-αγωνιστη, μια ινσουλινη και μεθειονινη | |
| CY1117312T1 (el) | Θεραπευτικη αγωγη συνουκλεϊνοπαθειων | |
| EA201170149A1 (ru) | Новые аналоги инсулина пролонгированной активности | |
| CY1121203T1 (el) | Θεραπευτικες χρησεις της εμπαγλιφλοζινης | |
| CY1119952T1 (el) | Συνδυασμος μιας ινσουλινης και ενος glp-1-αγωνιστη | |
| CY1118616T1 (el) | Λιξισενατιδη ως προσθετη θεραπεια σε βασικη ινσουλινη σε διαβητη τυπου 2 | |
| CY1116424T1 (el) | Παραγωγο αδενινης ως αναστολεας ρι3κ | |
| PA8841701A1 (es) | Derivados heterocíclicos, procesos para su preparación, medicamentos que comprenden compuestos y su uso | |
| CY1118943T1 (el) | Anti-pd-l1 αντισωματα και χρηση αυτων για την ενισχυση της λειτουργιας τ-κυτταρων | |
| CY1115180T1 (el) | Επιλογες θεραπειας για τη νοσο του fabry | |
| CY1117250T1 (el) | Λιξισενατιδη και μετφορμινη για τη θεραπευτικη αγωγη διαβητη τυπου 2 | |
| CY1110889T1 (el) | C-αρυλο γλυκοζιτικοι sglt2 αναστολεις και μεθοδος για την παραγωγη τους | |
| CY1123398T1 (el) | Συνθεση συνδυασμου | |
| CY1116799T1 (el) | Προληψη της υπογλυκαιμιας σε ασθενεις με σακχαρωδη διαβητη τυπου 2 | |
| ATE534378T1 (de) | Titrierung von tapentadol |